Core Viewpoint - The recent announcement by Vaili Zhibo has not garnered significant market attention despite the potential of its core product reaching key R&D milestones, which typically attracts investor interest in the Hong Kong stock market for unprofitable 18A companies [3][4]. Market Reaction - Following the announcement, Vaili Zhibo's stock price rose by 3.15% and 1.44% on January 15 and 16, respectively, but subsequently experienced a "three consecutive declines" trend, influenced by the overall pullback in the Hong Kong medical sector and the upcoming cornerstone lock-up expiration [3][4]. - The Hang Seng Healthcare Index reached a peak of 4326.18 points on January 15 before entering a "four consecutive down" trend, indicating a market correction after a period of gains [4]. Trading Volume and Technical Analysis - Vaili Zhibo experienced a "seven consecutive up" trend from December 30 to January 8, coinciding with the company's participation in the JPM conference, but this rally lacked substantial trading volume support, indicating a potential "false breakout" in technical terms [6][8]. - The daily trading volume peaked at 224.58 million shares at the start of the rally but subsequently declined, suggesting a lack of market support and leading to a downward price trend [6]. Cornerstone Lock-up Expiration - Vaili Zhibo's cornerstone investors, who collectively subscribed for $69 million (approximately 542 million HKD) during the IPO, will face a lock-up expiration on January 25, 2025, which could lead to profit-taking and market pressure [8][10]. - As of January 21, the stock price was 51.25 HKD, indicating that cornerstone investors have an approximate 50% unrealized gain, providing them with a favorable exit opportunity [8]. Future Market Dynamics - The upcoming inclusion of Vaili Zhibo in the Hong Kong Stock Connect program in March 2025, with an average market capitalization of 9.462 billion HKD, positions it as a potential target for new capital inflows [10][12]. - The behavior of cornerstone investors during the lock-up expiration will serve as a critical indicator for market sentiment and could influence the stock's performance in the context of new capital entering the market [10][14]. Company Fundamentals - Vaili Zhibo's innovative strategy focuses on T cell connectors, tumor immunology 2.0, and antibody-drug conjugates, with its core product LBL-024 being a significant asset in its pipeline [13][14]. - LBL-024 has received fast track designation from the FDA for treating neuroendocrine cancer, highlighting its potential and the recognition from regulatory bodies [13].

1月14日晚，维立志博-B(09887)发布公告，宣布其在研核心品种抗PD-L1/4-1BB双特异性抗体维利信®(LBL-024)获得美国食品药品监督管理局(FDA)授予快 速通道资格认定，用于治疗肺外神经内分泌癌(EP-NEC)。 对于一家未盈利的港股18A企业而言，在暂时没有商业化里程碑的发展前期，有巨大潜力的核心品种到达关键研发里程碑，往往都会引发场内投资者关注并 获得市场配置，这也是港股不少18A标的走出阶段性上涨行情的原因之一。然而，维立志博此次重磅公告披露似乎并未得到相应关注。 智通财经APP观察到，在维立志博发布公告后，公司股价分别在1月15日和16日分别收涨了3.15%和1.44%，之后便迎来一个"三连跌"跳水行情。而这一方面 与港股医药板块回调有关(1月15日至20日，恒生医疗保健指数走出"四连跌")，另一方面或与维立志博即将基石解禁有关。 板块"跳水"叠加基石解禁，观望情绪主导市场 1月15日，随着JPM大会的落幕，港股医药板块也在充分定价各种会议利好后，进入了利好兑现期。此外，截至目前多家医药公司将陆续发布2025年全年业 绩预告。在规避市场不确定性的逻辑下，投资者通常会选择观望。 在上 ...

Core Insights - The article discusses the IPO progress of Aimi Biotech, a pioneer in next-generation bispecific antibodies, focusing on its innovative T cell engagers (TCE) for cancer and autoimmune disease treatment [1][2]. Group 1: Company Overview - Aimi Biotech is at the forefront of the bispecific antibody treatment field, aiming to develop TCEs globally for various cancers and autoimmune diseases [1]. - The company plans to use the net proceeds from the IPO primarily for clinical development of core products, pipeline expansion, and operational funding [1]. - Aimi Biotech has a strong leadership team with extensive industry experience, including founder Dr. Wu Chenbing and Chief Medical Officer Dr. Zhu Yonghong, which supports its strategic execution and technology transfer [2]. Group 2: Technology and Product Pipeline - Aimi Biotech has developed proprietary technology platforms, including FIT-Ig, MAT-Fab, and a CD3 antibody library, which are crucial for advancing bispecific antibody development [2][3]. - The FIT-Ig platform is unique as it does not require amino acid mutations or linker peptides, with clinical projects like EMB-01 and EMB-06 already in advanced stages [3]. - The company has established seven product pipelines covering oncology and immunology, including key products EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [2]. Group 3: Market Potential and Collaborations - The global bispecific antibody market is projected to reach $221.8 billion by 2034, with a compound annual growth rate (CAGR) of 32.4% from 2024 to 2034 [1]. - Aimi Biotech has secured multiple licensing agreements since the end of 2023, with a total transaction value exceeding $2.1 billion, ranking second globally in the TCE field [4]. - The company is positioned to accelerate the commercialization of innovative drugs, enhancing its competitive edge in the rapidly growing bispecific antibody and TCE treatment markets [4].